Patents by Inventor Fuming Xu
Fuming Xu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220411432Abstract: The present disclosure provides compounds represented by Formula I-A: A1-L1-B1??I-A and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein A1, B1, and L1 are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I-A for use to treat a condition or disorder responsive to degradation of MDM2 protein such as cancer.Type: ApplicationFiled: August 31, 2021Publication date: December 29, 2022Inventors: Shaomeng Wang, Yangbing Li, Jiuling Yang, Angelo Aguilar, Bing Zhou, Jiantao Hu, Fuming Xu, Rohan Rej, Xin Han
-
Publication number: 20220356192Abstract: The present disclosure provides compounds represented by Formula I: I, and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1, R2a, R2b, R3, R4, Ar, L, X, Y, and B are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to degradation of BET bromodomains such as cancer.Type: ApplicationFiled: April 12, 2021Publication date: November 10, 2022Inventors: Shaomeng Wang, Yang Hu, Chong Qin, Fuming Xu, Jiantao Hu, Weiguo Xiang, Bing Zhou
-
Patent number: 11466028Abstract: The present disclosure provides compounds represented by Formula I and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, R4, Ar, L, X, Y, and B are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to degradation of BET bromodomains such as cancer.Type: GrantFiled: September 13, 2017Date of Patent: October 11, 2022Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Shaomeng Wang, Yang Hu, Chong Qin, Fuming Xu, Jiantao Hu, Bing Zhou, Zhuo Chen, Ester Fernandez-Salas, Longchuan Bai, Donna McEachern
-
Patent number: 11337782Abstract: Disclosed is a dental implant distractor, including an implant module and a traction module. The implant module includes an implant, a sealing screw, and a base body. The traction module includes a connecting screw rod, a traction screw rod, an inner sleeve, and an outer sleeve; the connecting screw rod is threadedly connected to the base body; the traction screw rod is located below the connecting screw rod; the inner sleeve is provided below the base body. This apparatus can automatically complete the installation of the base body and the sealing of the connecting screw rod after traction is completed; since the installation of the base body and the sealing do not need to be performed again, operation steps are simplified, the clinical operation difficulty is reduced, and the problem of slippage of an upper bone section to the original position is avoided.Type: GrantFiled: December 27, 2017Date of Patent: May 24, 2022Inventors: Chenping Zhang, Jiannan Liu, Fuming Xu, Xingzhou Qu, Jizhuang Ma
-
Publication number: 20220079931Abstract: The present disclosure provides compounds represented by Formula (I): A-L-B and the salts or solvates thereof, wherein A, L, and B are as defined in the specification. Compounds having Formula I are estrogen receptor degraders useful for the treatment of cancer.Type: ApplicationFiled: December 19, 2019Publication date: March 17, 2022Inventors: Shaomeng Wang, Jiantao Hu, Biao Hu, Mingliang Wang, Fuming Xu, Bukeyan Miao
-
Patent number: 11267822Abstract: The present disclosure provides compounds represented by Formula (I): Formula (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, R4, Y, ?, Ar, W, L, and B are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I)I for use to treat a condition or disorder responsive to inhibition and/or degradation of BET bromodomains such as cancer.Type: GrantFiled: September 12, 2018Date of Patent: March 8, 2022Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Shaomeng Wang, Weiguo Xiang, Fuming Xu, Longchuan Bai, Ester Fernandez-Salas, Donna McEachern
-
Patent number: 11192898Abstract: The present disclosure provides compounds represented by Formula I-A: A1-L1-B1 I-A and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein A1, B1, and L1 are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I-A for use to treat a condition or disorder responsive to degradation of MDM2 protein such as cancer.Type: GrantFiled: April 6, 2017Date of Patent: December 7, 2021Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Shaomeng Wang, Yangbing Li, Jiuling Yang, Angelo Aguilar, Bing Zhou, Jiantao Hu, Fuming Xu, Rohan Rej, Xin Han
-
Publication number: 20210353610Abstract: The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein R1a, R1b, R1c, E, G, and Q are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat cancer or any other disease, condition, or disorder that is responsive to inhibition of menin.Type: ApplicationFiled: September 30, 2019Publication date: November 18, 2021Inventors: Shaomeng WANG, Shilin XU, Angelo AGUILAR, Liyue HUANG, Tianfeng XU, Meng ZHANG, Renqi XU, Fuming XU, Haibin ZHOU, Tao LIU
-
Publication number: 20210322137Abstract: Disclosed is a dental implant distractor, comprising an implant module and a traction module. The implant module comprises an implant, a sealing screw, and a base body. The traction module comprises a connecting screw rod, a traction screw rod, an inner sleeve, and an outer sleeve; the connecting screw rod is threadedly connected to the base body; the traction screw rod is located below the connecting screw rod; the inner sleeve is provided below the base body. This apparatus can automatically complete the installation of the base body and the sealing of the connecting screw rod after traction is completed; since the installation of the base body and the sealing do not need to be performed again, operation steps are simplified, the clinical operation difficulty is reduced, and the problem of slippage of an upper bone section to the original position is avoided.Type: ApplicationFiled: December 27, 2017Publication date: October 21, 2021Applicants: SHANGHAI NINTH PEOPLES HOSPITAL AFFILIATED SHANGHAI JIAOTONG UNIVERSITY SCHOOL OF MEDICINE, SHANGHAI JINGTANG MEDICAL APPARATUS AND INSTRUMENTS LIMITEDInventors: Chenping ZHANG, Jiannan LIU, Fuming XU, Xingzhou QU, Jizhuang MA
-
Publication number: 20210284657Abstract: The present disclosure provides compounds represented by Formula I and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, R4, Ar, L, X, Y, and B are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to degradation of BET bromodomains such as cancer.Type: ApplicationFiled: September 13, 2017Publication date: September 16, 2021Inventors: Shaomeng Wang, Yang Hu, Chong Qin, Fuming Xu, Jiantao Hu, Bing Zhou, Zhuo Chen, Ester Fernandez-Salas, Longchuan Bai, Donna McEachern
-
Patent number: 11046709Abstract: The present disclosure provides fused 1,4-diazepines represented by Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein A, E, R1, R2, R3, R4, R5, and Ar are as defined as set forth in the specification. The present disclosure is also directed to the use of compounds having Formula (I) to treat diseases, conditions, or disorders responsive to inhibition of BET bromodomain proteins such as cancer.Type: GrantFiled: February 2, 2018Date of Patent: June 29, 2021Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Shaomeng Wang, Jiantao Hu, Fuming Xu
-
Patent number: 10975093Abstract: The present disclosure provides compounds represented by Formula I: I, and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1, R2a, R2b, R3, R4, Ar, L, X, Y, and B are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to degradation of BET bromodomains such as cancer.Type: GrantFiled: September 13, 2017Date of Patent: April 13, 2021Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Shaomeng Wang, Yang Hu, Chong Qin, Fuming Xu, Jiantao Hu, Weiguo Xiang, Bing Zhou
-
Publication number: 20210002289Abstract: The present disclosure provides compounds represented by Formula I: and the salts or solvates thereof, wherein X, L, Y, and B are as defined in the specification. Compounds having Formula I are immunomodulators and/or monofunctional synthetic intermediates that can be used to prepare small-molecule drug conjugates.Type: ApplicationFiled: August 31, 2020Publication date: January 7, 2021Inventors: Yangbing Li, Angelo Aguilar, Bing Zhou, Jiantao Hu, Fuming Xu, Chong Qin, Yang Hu, Weiguo Xiang, Rohan Rej, Jiuling Yang, Xin Han, Longchuan Bai, Chao-Yie Yang
-
Publication number: 20200277305Abstract: The present disclosure provides compounds represented by Formula (I): Formula (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, R4, Y, ?, Ar, W, L, and B are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I)I for use to treat a condition or disorder responsive to inhibition and/or degradation of BET bromodomains such as cancer.Type: ApplicationFiled: September 12, 2018Publication date: September 3, 2020Inventors: Shaomeng Wang, Weiguo Xiang, Fuming Xu, Longchuan Bai, Ester Fernandez-Salas, Donna McEachern
-
Patent number: 10759808Abstract: The present disclosure provides compounds represented by Formula I: and the salts or solvates thereof, wherein X, L, Y, and B are as defined in the specification. Compounds having Formula I are immunomodulators and/or monofunctional synthetic intermediates that can be used to prepare small-molecule drug conjugates.Type: GrantFiled: April 6, 2017Date of Patent: September 1, 2020Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Shaomeng Wang, Yangbing Li, Angelo Aguilar, Bing Zhou, Jiantao Hu, Fuming Xu, Chong Qin, Yang Hu, Weiguo Xiang, Rohan Rej, Jiuling Yang, Xin Han, Longchuan Bai, Chao-Yie Yang
-
Patent number: 10633386Abstract: The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein B, R1, R5, Q1, Q?, L, X, Y, and Z are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to degradation of BET bromodomains such as cancer.Type: GrantFiled: April 6, 2017Date of Patent: April 28, 2020Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Shaomeng Wang, Bing Zhou, Fuming Xu, Jiantao Hu, Longchuan Bai, Chao-Yie Yang
-
Publication number: 20190382415Abstract: The present disclosure provides fused 1,4-diazepines represented by Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein A. E, R1, R2, R3, R4, R5, and Ar are as defined as set forth in the specification. The present disclosure is also directed to the use of compounds having Formula (I) to treat diseases, conditions, or disorders responsive to inhibition of BET bromodomain proteins such as cancer.Type: ApplicationFiled: February 2, 2018Publication date: December 19, 2019Inventors: Shaomeng Wang, Jiantao Hu, Fuming Xu
-
Publication number: 20190263827Abstract: The present disclosure provides compounds represented by Formula I: I, and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1, R2a, R2b, R3, R4, Ar, L, X, Y, and B are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to degradation of BET bromodomains such as cancer.Type: ApplicationFiled: September 13, 2017Publication date: August 29, 2019Inventors: Shaomeng Wang, Yang Hu, Chong Qin, Fuming Xu, Jiantao Hu, Weiguo Xiang, Bing Zhou
-
Publication number: 20190169195Abstract: The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein B, R1, R5, Q1, Q?, L, X, Y, and Z are as defined as set forth in the specification. The present disclosure also provids compounds of Formula I for use to treat a condition or disorder responsive to degradation of BET bromodomains such as cancer.Type: ApplicationFiled: April 6, 2017Publication date: June 6, 2019Inventors: Shaomeng Wang, Bing Zhou, Fuming Xu, Jiantao Hu, Longchuan Bai, Chao-Yie Yang
-
Publication number: 20190127387Abstract: The present disclosure provides compounds represented by Formula I-A: A1-L1-B1 I-A and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein A1, B1, and L1 are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I-A for use to treat a condition or disorder responsive to degradation of MDM2 protein such as cancer.Type: ApplicationFiled: April 6, 2017Publication date: May 2, 2019Inventors: Shaomeng Wang, Yangbing Li, Jiuling Yang, Angelo Aguilar, Bing Zhou, Jiantao Hu, Fuming Xu, Rohan Rej, Xin Han